Can you get Mounjaro on the NHS in Northern Ireland?
In short, not for routine weight loss prescribing, as far as the official information shows at the time of writing. The Department of Health has announced a phased, specialist-led service instead. The first phase, the Regional Obesity Management Service (ROMS), was expected to roll out in early autumn 2026, so check for the latest position before you plan around it.
Two things can be true at once. Prescriptions dispensed in Northern Ireland are free of charge for everyone, according to nidirect. But free prescriptions do not mean that a weight loss medicine is available to you on the NHS.
The Northern Ireland formulary leaflet on tirzepatide, dated April 2025, states that it is not currently available through the Health Service for obesity. That predates the June 2026 announcement, so treat it as a snapshot. The ROMS announcement does not name a drug, and we have not found an equivalent Northern Ireland statement for Wegovy, so check the Department's page for both.
What is the Regional Obesity Management Service (ROMS)?
The Department announced phase one of ROMS on 29 June 2026, with a budget of £5 million. Phase one is for adults aged 18 and over with a body mass index (BMI) above 45, plus at least one of the following:
- atherosclerotic cardiovascular disease, including stroke and heart failure
- hypertension (high blood pressure) that needs medication
- dyslipidaemia (abnormal levels of blood fats)
- obstructive sleep apnoea, confirmed by a sleep study
- type 2 diabetes
The Department says ROMS will enable access to weight loss medication "if clinically appropriate and in line with NICE guidance", alongside lifestyle support. Whether a medicine is offered is a clinical decision, not something the service guarantees.
Referral is meant to be flexible. The Department describes multiple routes, including self-referral and social prescribing, so you would not need a GP referral under those routes. Details of how the service will be delivered are promised "in due course", so ask what your local route involves before you plan around it.
What is the Obesity Pathway Innovation Programme (OPIP)?
OPIP is a separate programme for adults with a BMI between 30 and 39.9. The Department says delivery of OPIP starts in August 2026, with ROMS following in autumn 2026. The announcement describes weight management routes rather than a named medicine.
If your BMI is in this range and you want to know what is on offer, start with the latest information on health-ni.gov.uk. You can also ask your GP which local weight management services are open to you, and what you would need to show to be referred.
How Northern Ireland compares with England, Scotland and Wales
The position differs across the UK, and it is changing. The table summarises the position as reported at the time of writing. Check the government page for each nation before you rely on it.
| Nation | NHS position for weight loss | Main criteria reported |
|---|---|---|
| Northern Ireland | ROMS phase one from early autumn 2026; OPIP from August 2026 | ROMS: BMI above 45 plus a qualifying condition. OPIP: BMI 30 to 39.9 |
| England | NHS rollout of tirzepatide since June 2025, phased by integrated care board (ICB) | First phase, per ICB pages: BMI 40 or above (37.5 or above for some ethnic backgrounds) with at least four qualifying conditions. Some ICBs have said they may tighten access |
| Scotland | The Scottish Medicines Consortium accepted tirzepatide for restricted use in 2024 | Reported as BMI 30 or above with at least one weight-related condition, with rollout phased by clinical need |
| Wales | Prescribed through specialist NHS weight management services | Welsh Government guidance. A Senedd research briefing, last updated in November 2025, said work was still under way on wider availability |
Being offered treatment on paper is not the same as getting it in practice. Scottish and English criteria have been described as uneven in practice, so ask your local service how it applies them.
Why being licensed does not mean you qualify for NHS treatment
The licence and NHS eligibility are not the same thing. The Mounjaro summary of product characteristics (SmPC) describes use as an adjunct to a reduced-calorie diet and increased physical activity for weight management. It applies to adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, such as hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.
NHS commissioning is narrower. NICE's guidance on tirzepatide for overweight and obesity (TA1026), as summarised by secondary sources, recommends it for adults with a BMI of at least 35 and at least one weight-related comorbidity, with lower thresholds for some ethnic groups. So a licensed medicine may be prescribed privately for someone the NHS would not yet treat.
Private prescriptions are available from some providers and are not NHS treatment. Our guide to buying safely explains how to check a provider before you pay.
What to do now if you want NHS treatment
- Check health-ni.gov.uk for the current ROMS and OPIP position in your area, and whether your local route has opened.
- If you have one of the qualifying conditions, or a BMI in the OPIP range, ask your GP about your options and whether a referral route suits you.
- Keep a note of your height, weight and any diagnoses. That will help whichever service you approach.
- Use the eligibility checker for general information, not as a decision about treatment.
If the NHS route is not open to you yet, ask your GP about the lifestyle support in OPIP or any local weight management service, and whether a dietitian can help in the meantime. The ROMS announcement describes lifestyle support alongside any medicine, but it does not yet say which professionals will provide it.
Decisions about whether a medicine is suitable are made by a clinician. If you want to understand how these medicines work before you talk to one, read how weight loss injections work.